RBC Europe’s Adaptimmune Therapeutics ADAP Stock Holding History

RBC Europe’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,050	Closed	-$36.4K	–	633
2021 Q3	$36.4K	Hold	7,050	–	–	﹤0.01%	647
2021 Q2	$30K	Buy	+7,050	New	+$34.2K	﹤0.01%	715
2019 Q3	–	Sell	-600	Closed	-$2.41K	–	1057
2019 Q2	$2.41K	Hold	600	–	–	﹤0.01%	973
2019 Q1	$2.58K	Hold	600	–	–	﹤0.01%	980
2018 Q4	$3.45K	Hold	600	–	–	﹤0.01%	954
2018 Q3	$8.14K	Hold	600	–	–	﹤0.01%	886
2018 Q2	$7.12K	Hold	600	–	–	﹤0.01%	913
2018 Q1	$6.74K	Hold	600	–	–	﹤0.01%	910
2017 Q4	$4.01K	Hold	600	–	–	﹤0.01%	993
2017 Q3	$4.91K	Buy	+600	New	+$3.75K	﹤0.01%	952

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RBC Europe's ADAP Position: Q4 2021 in Review

RBC Europe sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 7,050 shares — an estimated $36.4K sold.

RBC Europe first reported a position in ADAP in Q3 2017 and held it in 10 quarters. The position peaked at $36.4K in Q3 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

RBC Europe reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 7,050 Adaptimmune Therapeutics shares in Q4 2021, an estimated $36.4K.
RBC Europe first reported a position in Adaptimmune Therapeutics in Q3 2017 and held it in 10 quarters.
RBC Europe's Adaptimmune Therapeutics position peaked at $36.4K in Q3 2021.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.